Eli Lilly and Company (NYSE:LLY) Price Target Increased to $1,025.00 by Analysts at Barclays

Eli Lilly and Company (NYSE:LLY) had its target price hoisted by Barclays from $913.00 to $1,025.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s target price would suggest a potential upside of 9.04% from the stock’s current price.

LLY has been the topic of several other research reports. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Bank of America reissued a “buy” rating and set a $1,000.00 target price on shares of Eli Lilly and Company in a research report on Monday, June 24th. Jefferies Financial Group lifted their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $828.72.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $939.98 on Wednesday. Eli Lilly and Company has a fifty-two week low of $434.34 and a fifty-two week high of $945.69. The stock has a market cap of $893.37 billion, a price-to-earnings ratio of 138.44, a PEG ratio of 2.00 and a beta of 0.41. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The firm’s 50-day simple moving average is $841.60 and its 200 day simple moving average is $758.80.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the firm earned $1.62 EPS. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, research analysts anticipate that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,004,704 shares of company stock worth $869,479,116. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of LLY. Raleigh Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 38.3% during the third quarter. Raleigh Capital Management Inc. now owns 148 shares of the company’s stock valued at $79,000 after buying an additional 41 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its holdings in shares of Eli Lilly and Company by 5.2% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 6,452 shares of the company’s stock valued at $3,761,000 after buying an additional 319 shares during the last quarter. Trust Co. of Toledo NA OH grew its holdings in shares of Eli Lilly and Company by 3.9% during the fourth quarter. Trust Co. of Toledo NA OH now owns 27,922 shares of the company’s stock valued at $16,276,000 after buying an additional 1,046 shares during the last quarter. HWG Holdings LP grew its holdings in shares of Eli Lilly and Company by 3.9% during the fourth quarter. HWG Holdings LP now owns 4,665 shares of the company’s stock valued at $2,719,000 after buying an additional 174 shares during the last quarter. Finally, InTrack Investment Management Inc grew its holdings in shares of Eli Lilly and Company by 15.9% during the fourth quarter. InTrack Investment Management Inc now owns 4,078 shares of the company’s stock valued at $2,377,000 after buying an additional 558 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.